Highlights:
• NOX to seek approval from U.S. FDA for clinical study of Veyonda® in COVID-19patients
• Objective to block progression of patients with early-stage disease into multi-organfailure and likely death
• Rationale based on inhibition of STING signaling
For more information, please download the attached PDF
Download this document
